Acute Lymphoblastic Leukemia, Pediatric

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Acute Lymphoblastic Leukemia, Pediatric is an early-stage landscape with 3 programs across 3 companies. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Preclinical

No programs

Phase 1

No programs

Phase 2

No programs

Phase 33

Pegaspargase

Servier

Erwinia Asparaginase

Amgen

Dasatinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

No programs

Analysis

clinical trials

Recruiting2 · 67%

Active, not recruiting1 · 33%

Clinical Trials

Recruiting·—·Phase 2·NCT06257394·74 enrolled

Active, not recruiting·DDana-Farber Cancer Institute·Phase 3·NCT03020030·560 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)